---
title: "Vivos Therapeutics, Inc. (VVOS.US)"
type: "Symbol"
locale: "en"
url: "https://longbridge.com/en/quote/VVOS.US.md"
symbol: "VVOS.US"
name: "Vivos Therapeutics, Inc."
industry: "Health Care Services"
datetime: "2026-05-20T10:34:55.254Z"
locales:
  - [en](https://longbridge.com/en/quote/VVOS.US.md)
  - [zh-CN](https://longbridge.com/zh-CN/quote/VVOS.US.md)
  - [zh-HK](https://longbridge.com/zh-HK/quote/VVOS.US.md)
---

# Vivos Therapeutics, Inc. (VVOS.US)

## Company Overview

Vivos Therapeutics, Inc. operates as a medical technology and healthcare services company that develops and commercializes treatment modalities for patients with dentofacial abnormalities, obstructive sleep apnea (OSA), and snoring in adults. It offers The Vivos Method, a non-invasive, non-surgical, non-pharmaceutical, multi-disciplinary treatment modality for the treatment of dentofacial abnormalities, OSA, and snoring. The company also offers VivoScore Program, a screening and home sleep test in adults and children.

| Item | Detail |
|------|--------|
| Industry | Health Care Services |
| Exchange | US Market |
| Website | [www.vivos.com](https://www.vivos.com) |

## Key Drivers
> *AI-analyzed key factors driving this stock's performance*


## Longbridge Financial Score™: C
> *Longbridge Financial Score™ — Proprietary multi-factor rating model by Longbridge*
> Updated: 2026-05-20T04:30:15.000Z

**Overall: C (0.56)**

**Industry**: Health Care Services

| Metric | Value |
|--------|-------|
| Industry Ranking | 60 / 87 |
| Industry Median | C |
| Industry Average | C |

- **Style**: Value - Stocks where the company's main business is in a mature stage.
- **Scale**: Small - The company's operation has a high degree of growth and volatility, making it easy to achieve high investment returns.

**Multi Score**: C

#### Style Score Score: 

| Indicator | Value | Rating |
|-----------|-------|--------|
| Revenue YoY | 16.05% |  |
| Net Profit YoY | -90.10% |  |
| P/B Ratio | -5.30 |  |
| Dividend Ratio | 0.00% |  |

#### Size Score Score: 

| Indicator | Value | Rating |
|-----------|-------|--------|
| Market Cap | 7890662.11 |  |
| Revenue | 17443000.00 |  |

#### Multi Score Score: C

| Indicator | Value | Rating |
|-----------|-------|--------|
| ROE | -655.01% | E |
| Profit Margin | -121.37% | E |
| Gross Margin | 60.44% | A |
| Revenue YoY | 16.05% | B |
| Net Profit YoY | -90.10% | E |
| Total Assets YoY | 64.56% | A |
| Net Assets YoY | -119.49% | E |
| Cash Flow Margin | 72.10% | C |
| OCF YoY | 16.05% | B |
| Turnover | 0.86 | B |
| Gearing Ratio | 106.16% | E |

```chart-data:radar
{
  "title": "Longbridge Financial Score - Vivos Therapeutics, Inc.",
  "chart_type": "radar",
  "dimensions": [
    {
      "name": "Style Score",
      "grade": "",
      "indicators": [
        {
          "name": "Revenue YoY",
          "value": "16.05%",
          "rating": ""
        },
        {
          "name": "Net Profit YoY",
          "value": "-90.10%",
          "rating": ""
        },
        {
          "name": "P/B Ratio",
          "value": "-5.30",
          "rating": ""
        },
        {
          "name": "Dividend Ratio",
          "value": "0.00%",
          "rating": ""
        }
      ]
    },
    {
      "name": "Size Score",
      "grade": "",
      "indicators": [
        {
          "name": "Market Cap",
          "value": "7890662.11",
          "rating": ""
        },
        {
          "name": "Revenue",
          "value": "17443000.00",
          "rating": ""
        }
      ]
    },
    {
      "name": "Multi Score",
      "grade": "C",
      "indicators": [
        {
          "name": "ROE",
          "value": "-655.01%",
          "rating": "E"
        },
        {
          "name": "Profit Margin",
          "value": "-121.37%",
          "rating": "E"
        },
        {
          "name": "Gross Margin",
          "value": "60.44%",
          "rating": "A"
        },
        {
          "name": "Revenue YoY",
          "value": "16.05%",
          "rating": "B"
        },
        {
          "name": "Net Profit YoY",
          "value": "-90.10%",
          "rating": "E"
        },
        {
          "name": "Total Assets YoY",
          "value": "64.56%",
          "rating": "A"
        },
        {
          "name": "Net Assets YoY",
          "value": "-119.49%",
          "rating": "E"
        },
        {
          "name": "Cash Flow Margin",
          "value": "72.10%",
          "rating": "C"
        },
        {
          "name": "OCF YoY",
          "value": "16.05%",
          "rating": "B"
        },
        {
          "name": "Turnover",
          "value": "0.86",
          "rating": "B"
        },
        {
          "name": "Gearing Ratio",
          "value": "106.16%",
          "rating": "E"
        }
      ]
    }
  ]
}
```

## Valuation Analysis

| Metric | Current | Industry Ranking | High | Median | Low |
|--------|---------|-----------------|------|--------|-----|
| PE (TTM) | -0.37 | 35/87 | - | - | - |
| PB | -5.30 | 64/87 | 7.35 | 6.07 | 4.45 |
| PS (TTM) | 0.45 | 15/87 | 1.77 | 1.12 | 0.87 |
| Dividend Yield | 0.00% | - | - | - | - |

## Peer Comparison

| Rank | Name | Profit | Growth | Operation | Security | Cash | Rating |
| --- | --- | --- | --- | --- | --- | --- | --- |
| 01 | Cigna (CI.US) | B | C | A | D | B | B |
| 02 | BrightSpring Health Services - Unit (BTSGU.US) | C | A | A | D | B | B |
| 03 | Fresenius (FSNUY.US) | C | B | C | C | B | B |
| 04 | Quest Diagnostics (DGX.US) | B | B | B | C | B | B |
| 05 | Labcorp (LH.US) | B | B | B | C | B | B |

## Institutional View

### Analyst Rating Distribution

> As of 2026-04-22T04:00:00.000Z

Total Analysts: **4**

| Rating | Count | Percentage |
|--------|-------|-----------| 
| Buy | 2 | 50% |
| Hold | 1 | 25% |

### Target Price Forecast

| Metric | Price |
|--------|-------|
| Current Price | 0.59 |
| Highest Target | 3.00 |
| Lowest Target | 1.75 |

## References

- [Company Overview — Profile, executives, shareholders, business breakdown](https://longbridge.com/en/quote/VVOS.US/overview.md)
- [Financial Reports — Income, balance sheet, cash flow, dividends](https://longbridge.com/en/quote/VVOS.US/norm.md)
- [Related News](https://longbridge.com/en/quote/VVOS.US/news.md)
- [Filings — Company announcements and regulatory filings](https://longbridge.com/en/quote/VVOS.US/filings.md)

---

> **Disclaimer: This article is for reference only and does not constitute any investment advice.**